WHO validates China’s Convidecia as 11th vaccine for COVID-19

The World Health Organisation (WHO) has issued an emergency use listing (EUL) for Convidecia, a vaccine manufactured by CanSino Biologics, China, adding to a growing portfolio of vaccines validated by WHO for the prevention of COVID-19 caused by SARS-CoV-2. In addition to shortening the vaccination cycle by leveraging the advantages of its single-dose regimen, Convidecia can be stably transported and stored between 2 and 8 degrees celsius, making it more accessible to developing countries with insufficient storage facilities and medical resources, reducing the burden placed on healthcare systems and medical workers, and contributing to building broad immune protection globally. Currently, CanSinoBIO’s Convidecia has received approvals in more than 10 markets: China, Mexico, Ecuador, Chile, Argentina, Hungary, Kyrgyzstan, Pakistan, United Arab Emirates, Indonesia & Malaysia. The company also established local partnerships for distribution in various countries, including setting up fill-and-finish facilities in Mexico, Pakistan, & Malaysia, allowing its COVID-19 vaccine access to more people in developing markets.